01 Long-Acting Treatments Make MS Management More Convenient The multiple sclerosis drugs market is moving toward treatments that can provide sustained disease control while making long-term therapy easier for patients. Disease-modifying therapies are increasingly available in oral, injectable, and infusion forms, giving neurologists more options based on disease activity, treatment response, and patient needs. The continued focus on reducing relapses and slowing disability progression is supporting the multiple sclerosis drugs market growth as treatment strategies become more personalized. For instance, in November 2025, the U.S. FDA approved the first generic versions of cladribine tablets and diroximel fumarate capsules for relapsing forms of multiple sclerosis. The approvals expanded the availability of lower-cost alternatives to established MS treatments, potentially improving treatment access for eligible patients.
02 Safety Monitoring Becomes More Important in MS Treatment As patients may remain on MS therapies for many years, healthcare providers are paying closer attention to treatment safety and long-term monitoring. Regulators are continuing to review safety information and update prescribing guidance when new risks emerge. This focus is shaping prescribing decisions and encouraging drug manufacturers to develop therapies with improved safety and tolerability profiles, contributing to the increasing multiple sclerosis drugs market size. For instance, in January 2025, the FDA added a boxed warning to glatiramer acetate products, including Copaxone and Glatopa, regarding the risk of rare but serious anaphylactic reactions. The FDA noted that these reactions could occur even after patients had been using the medicine for months or years, highlighting the importance of continued safety monitoring during MS treatment.
01 Growing Need for Disease-Modifying Treatments and More Convenient Therapies The market is supported by the continuing need for treatments that reduce relapses, slow disease progression, and control disease activity in people with multiple sclerosis.Greater attention to earlier treatment, personalized care, and convenient dosing is encouraging pharmaceutical companies to develop therapies that are easier for patients to use while maintaining disease control. These developments are strengthening multiple sclerosis drugs market demand.
01 High Treatment Costs and Long-Term Therapy Requirements The market faces pressure from the high cost of many disease-modifying therapies, particularly biologic treatments and advanced infusion therapies. Multiple sclerosis is a chronic condition, so patients may require treatment and monitoring for many years. This creates a substantial financial burden for healthcare systems and patients, especially where reimbursement is limited. Safety monitoring and treatment-related adverse effects can add further costs.
01 Expansion of Oral Therapies and Earlier Disease Management The market has significant opportunities in oral therapies, targeted immunomodulators, and treatments designed to address different stages and forms of MS. Continued research into disease mechanisms and biomarkers is also creating opportunities for more personalized treatment strategies. These developments are shaping important multiple sclerosis drugs market trends.
01 Addressing Disease Progression and Maintaining Long-Term Treatment Response The market continues to face the challenge of developing therapies that can effectively control MS over the long term while minimizing adverse effects. Although existing disease-modifying treatments can reduce relapse activity, patients can respond differently to therapy, and some may continue to experience disability progression. Developing treatments that address progressive forms of MS remains particularly important.
May 2026 Sanofi announced positive Phase III clinical results for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, supporting future regulatory submissions.
March 2026 Novartis received European Commission approval for an expanded indication of Kesimpta, strengthening its multiple sclerosis treatment portfolio across Europe.
September 2025 TG Therapeutics expanded the commercial availability of Briumvi through new patient support initiatives, strengthening access to anti-CD20 therapy for relapsing multiple sclerosis.
May 2025 Roche received U.S. FDA approval for a new subcutaneous formulation of Ocrevus, reducing administration time while expanding treatment options for patients with relapsing and primary progressive multiple sclerosis.